ASCO 2022 – the spirit of Rova-T struggles to live on

When Abbvie’s Rova-T crashed and burned many might have assumed that DLL3 blockade was finished as an oncology drug mechanism. Not so: through an Asco poster covering its T-cell engager HPN328, Harpoon Therapeutics today continued a tenuous bid to join Amgen and Boehringer Ingelheim among a small group of companies working clinically on this mechanism of action.